From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-07770-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Kaat Spoormans und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medical Applications, Belgian Nuclear Research Center (SCK CEN), Mol, 2400, Belgium. Spoormanskaat@hotmail.com. Hauptthemen laut MEDLINE: Octreotide, Organometallic Compounds, Models, Biological, Terbium. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Knowledge of tumor absorbed dose (AD)–response relationships is a critical first step toward personalizing dose regimens. This study investigated these relationships at a preclinical scale and modeled the observed tumor growth by considering both cellular AD-response relationships and tumor AD distributions. Using this framework, we compared the tumor AD-response of [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE. METHODS: CA20948 xenograft-bearing mice were injected with a range of activities of [177Lu]Lu-DOTATATE (1 nmol, 21.6–115.4 MBq) and [161Tb]Tb-DOTATATE (1 nmol, 17.3–91.7 MBq). The tumor doubling time was measured and correlated with individual tumor AD, determined with micro-SPECT imaging. The tumor-growth was also modeled based on cellular AD-response relationships, while considering subtumor AD distributions that were determined either with digital autoradiography or micro-SPECT. RESULTS: [161Tb]Tb-DOTATATE showed a 30% higher S-value for tumors compared to [177Lu]Lu-DOTATATE, after a correction for subcellular heterogeneity. Both treatments reached a clinically relevant tumor AD-range of 9–85 Gy and 5–87 Gy, respectively. A positive correlation was observed between the tumor doubling time and the tumor AD (p < 0.0001, R2 = 0.58), with no significant difference in AD-response between [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE (p = 0.24). The performance of the tumor-growth-model improved substantially after considering AD heterogeneity (from R2 = -64 up to R2 = 0.16). CONCLUSION: The tumor doubling time showed a positive correlation with the tumor AD which was largely affected by the heterogeneous AD distribution within the tumor. Findings confirm that [161Tb]Tb-DOTATATE does not increase the therapeutic efficacy compared to [177Lu]Lu-DOTATATE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medical Applications, Belgian Nuclear Research Center (SCK CEN), Mol, 2400, Belgium. Spoormanskaat@hotmail.com.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, 3000, Belgium. Spoormanskaat@hotmail.com.
- Nuclear Medical Applications, Belgian Nuclear Research Center (SCK CEN), Mol, 2400, Belgium.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, 3000, Belgium.
ORCID-Profile: Kaat Spoormans
Zitieren
APA
Spoormans, K., Struelens, L., Koole, M., & Crabbé, M. (2026). From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07770-0
Vancouver
Spoormans K, Struelens L, Koole M, Crabbé M. From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07770-0
BibTeX
@article{Spoormans2026,
author = {Spoormans, Kaat and Struelens, Lara and Koole, Michel and Crabbé, Melissa},
title = {From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-07770-0}
}
EUVIMED